TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tvardi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.97−0.04 (-3.96%)
Close on Oct 19, 2026
- Market cap
- $9.10M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Tvardi Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q1 22 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other revenue (non-cash) [Member] | $5.03M | $4.33M | $3.57M | $2.31M | $1.32M | $699.00K | – | – | – | – | – | – | 39.9% | +280.3% |
| Other revenue | $5.03M | $4.33M | – | – | – | – | – | – | – | – | – | – | 39.9% | – |
| Collaborative revenue | $2.50M | $2.09M | $4.39M | $5.56M | $10.97M | $12.94M | $11.76M | $16.73M | $19.32M | $16.57M | – | $706.00K | 19.8% | -77.3% |
| Clinical compound revenue | $48.00K | $84.00K | $84.00K | $150.00K | $150.00K | $165.00K | – | – | – | – | – | $398.00K | 0.4% | -68.0% |
| License and milestone fees [Member] | – | – | – | – | – | $910.00K | – | – | – | $15.00M | – | $21.22M | – | – |
| Royalty revenue | – | – | – | – | – | $415.00K | – | – | – | – | $0 | $0 | – | – |
| Commercial supply revenue | – | $640.00K | $640.00K | $1.89M | $3.29M | $5.84M | $7.91M | $10.02M | $8.62M | $10.22M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Tvardi Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.